Saleh Shamse Basha: Severe Neonatal Anemia – When the Analyzer Tells a Story Before the Slide Does
Saleh Shamse Basha, Senior Hematology Technologist (Reference Lab, HQ) at PureLab, shared a post on LinkedIn:
“Case Discussion: Severe Neonatal Anemia – When the Analyzer Tells a Story Before the Slide Does
A newborn presented with Hb: 49 g/L, a critical value that immediately raises the question: hemolysis or hemorrhage?
Analyzer Findings (Sysmex XR-9000)
By looking at the WDF and WNR scattergrams, I felt something unusual – more striking than the critically low hemoglobin itself.
- TNC (Total Nucleated Cell): 78.74
- WBC: 11.26
- NRBC : 576/100 WBC
- Reticulocytes: 14%
The WNR channel is where the story begins.
It uses a lysing reagent that strips RBC and reticulocyte membranes but leaves NRBC nuclei intact, so both WBCs and NRBCs are counted together as the Total Nucleated Cell (TNC) count.
A related but separate issue appears on the WDF scattergram: immature NRBCs have larger nuclei that fall close to the WBC populations, sometimes overlapping the lymphocyte region and triggering a “WBC Abnormal Scattergram” flag.
When this happens, manual slide review and a true differential are essential in cases with marked NRBCs. The manual differential was very close to the analyzer count.
Blood Film
Marked anisopoikilocytosis with an elevated MCV, consistent with reticulocytosis.
Occasional target cells and schistocytes were also noted.
DAT: Negative, ruling out alloimmune hemolytic disease of the newborn.
Clinical History
Documented feto-maternal hemorrhage (FMH).
Interpretation
Putting it all together: severe anemia accompanied by reticulocytosis, marked NRBCs, a negative DAT, and a clinical history of feto-maternal hemorrhage is most consistent with acute or chronic blood loss anemia in the neonate secondary to massive FMH, rather than immune hemolysis.
The marrow response, evidenced by reticulocytosis together with marked NRBCs, is compensatory rather than causative.”

Stay updated with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian